Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window

 With reference to the captioned matter and above referred Circular, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed / amended pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for trading in securities of the Company will remain closed for the purpose of consideration of audited financial results and dividend for the financial year ended 31st March, 2019 with immediate effect till 48 hours after the declaration of the financial results. We request you to kindly take the same on record.
03-04-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015

 In compliance with the requirements of the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Board of Directors has amended Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information incorporating therein a policy for determination of 'Legitimate Purposes' ('Code of Fair Disclosures and Conduct'). The amended Code of Fair Disclosures and Conduct is effective from 1st April, 2019 and the same is available on the website of the Company at the following web-link: https://www.alembicpharmaceuticals.com/policiescodes/ We request you to kindly take the same on record.
01-04-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Re-Appointment Of Independent Directors

 With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee and the Board of Directors, the shareholders of the Company at their 8th Annual General Meeting held on 27th July, 2018 had approved by way of special resolution, the re-appointment of following Independent Directors of the Company for their second term of five consecutive years w.e.f. 1st April, 2019: 1. Mr. K. G. Ramanathan 2. Mr. Pranav Parikh 3. Mr. Paresh Saraiya The proceedings of the aforesaid Annual General Meeting was submitted with the exchange on 27th July, 2018. The above referred Independent Directors are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 is enclosed along with the covering letter. We request you to kindly take the same on record.
01-04-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s).
28-03-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg and 20 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
27-03-2019
Bigul

Alembic Pharma gets USFDA nod for conjunctivitis treatment drug

 Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Azelastine Hydrochloride Ophthalmic Soluti
22-03-2019
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Azelastine Hydrochloride Ophthalmic Solution, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
22-03-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) mentioned in the attached letter on 20th March, 2019.
20-03-2019
Bigul

Alembic Pharma raises Rs 150 cr via NCDs

 Drug firm Alembic Pharmaceuticals on Tuesday said it has raised Rs 150 crore through the allotment of non-convertible debentures (NCDs) on private pl
19-03-2019
Bigul

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Allotment

 With reference to the captioned matter, the exchange is hereby informed that the NCD Committee of Alembic Pharmaceuticals Limited at its meeting held today has allotted 1,500 (One Thousand Five Hundred) 8.37% Unsecured Listed Rated Redeemable Non-Convertible Debentures ('NCDs') of Rs. 10,00,000/- (Rs. Ten Lacs) per NCD aggregating to Rs. 150,00,00,000/- (Rs. One Hundred and Fifty Crores) under Tranche III. The detailed disclosure pursuant to Regulation 30(2) of Listing Regulations, 2015 for Tranche is enclosed herewith as Annexure - 1. The time of commencement of the NCD Committee Meeting was 10:00 a.m. and the time of conclusion was 10:30 a.m. We request you to kindly take the same on record.
19-03-2019
Next Page
Close

Let's Open Free Demat Account